
Gilead Sciences, Inc.
GILDHealthcare|Drug Manufacturers - General|US
$166.89
-0.68 (-0.41%)
DCF Value
$137.19
Cash / Share
$5.18
Next Earnings Report
Feb 9, 2027
EPS est. $1.39 · Revenue est. $8.28B
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Aug 6, 2026 (S-3ASR). Possible dilution.
Upcoming Data Readouts (57)
Dec 2026
Est. completion
P2Multiple Myeloma
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885n=136
Dec 2026
Est. completion
P1Localized Muscle Invasive Bladder Urothelial Carcinoma
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
NCT05833867n=20
Dec 2026
Est. completion
P2Biliary Tract Carcinoma
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
NCT06048133n=33
Dec 2026
Est. completion
P1Gastrointestinal Cancer
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
NCT06065371n=20
Dec 2026
Est. completion
P1Solid Tumors
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
NCT06082960n=45
Jan 2027
Est. completion
P2Ulcerative Colitis
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972n=176
Jan 2027
Est. completion
P2Stage III Breast Cancer
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT03971409n=145
Feb 2027
Est. completion
P1P2Breast Cancer
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT06238921n=31
Feb 2027
Est. completion
P3Triple Negative Breast Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286n=443
Feb 2027
Est. completion
P1P2Advanced Breast Cancer
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
NCT06612203n=76
Mar 2027
Est. completion
Metastatic Breast Cancer
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
NCT03275311n=42,000
Mar 2027
Est. completion
P2Head and Neck Squamous Cell Carcinoma
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565n=39
Mar 2027
Est. completion
P2Non-small Cell Lung Cancer
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974n=193
Mar 2027
Est. completion
P3HER2-negative Breast Cancer
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565n=1,332
Mar 2027
Est. completion
P4HIV
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
NCT07210125n=75
May 2027
Est. completion
P2Thymoma
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
NCT06248515n=18
May 2027
Est. completion
P2Breast Cancer
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
NCT06665178n=20
Jun 2027
Est. completion
P3Triple Negative Breast Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654n=1,514
Jun 2027
Est. completion
P4HIV -1 Infection
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
NCT07476339n=200
Jul 2027
Est. completion
Liver Cirrhosis
Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors
NCT07238114n=450
Awaiting Results (15)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P1
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
NCT05457010Oct 2026
P3
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
NCT05552001Sep 2026
P2
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
NCT02932150Apr 2026
P3
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299Oct 2025
P3
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808Jun 2025
P2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT05327530Mar 2025
P2P3
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
NCT02881320Recent Press Releases
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®'s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)
Nov 5, 2026 · Business Wire
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Nov 4, 2026 · Business Wire
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
Nov 2, 2026 · Business Wire
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
Oct 30, 2026 · Business Wire
Gilead Sciences Announces Third Quarter 2026 Financial Results
Oct 29, 2026 · Business Wire
The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme
Oct 23, 2026 · Business Wire
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Oct 22, 2026 · Business Wire
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
Oct 22, 2026 · Business Wire
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Oct 19, 2026 · Business Wire
Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
Sep 17, 2026 · Business Wire
SEC Filings (78)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 6, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Nov 6, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Oct 30, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Oct 29, 2026 | 8-K | Material event | DocumentIndex |
| Aug 26, 2026 | N-PX | DocumentIndex | |
| Aug 7, 2026 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| Aug 6, 2026 | S-3ASR | Shelf registration | DocumentIndex |
| Aug 6, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 4, 2026 | 8-K | Material event | DocumentIndex |
| Aug 3, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| May 27, 2026 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| May 20, 2026 | 8-K | Material event | DocumentIndex |
| May 18, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| May 14, 2026 | FWP | DocumentIndex | |
| May 14, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| May 8, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| May 7, 2026 | S-8 | Employee stock plan | DocumentIndex |
| May 7, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 7, 2026 | 8-K | Material event | DocumentIndex |
| May 4, 2026 | 8-K | Material event | DocumentIndex |
| Apr 29, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 28, 2026 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| Apr 28, 2026 | 8-K | Material event | DocumentIndex |
| Apr 28, 2026 | SC TO-T/A | Tender offer | DocumentIndex |
| Apr 17, 2026 | SC TO-T/A | Tender offer | DocumentIndex |
| Apr 1, 2026 | SC TO-T/A | Tender offer | DocumentIndex |
| Mar 26, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 20, 2026 | ARS | Annual report to holders | DocumentIndex |
| Mar 20, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Mar 20, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 6, 2026 | SC TO-T | Tender offer | DocumentIndex |
| Feb 24, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 23, 2026 | SC TO-C | Tender offer | DocumentIndex |
| Feb 23, 2026 | SC 13D | Activist / 5%+ stake | DocumentIndex |
| Feb 23, 2026 | SC TO-C | Tender offer | DocumentIndex |
| Feb 23, 2026 | 8-K | Material event | DocumentIndex |
| Feb 12, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 12, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Feb 12, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 10, 2026 | 8-K | Material event | DocumentIndex |